Financial health
- Operating income covered interest expense -1383.4× in the latest year.
- The company is unprofitable; at its current free-cash-flow burn it has roughly 1.5 years of cash runway.
BRNS Financials Barinthus Biotherapeutics plc.
6 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $0 | -$66M | — | — | -$48M | — | $70M |
| 2024 | $15M | -$61M | 0.0% | -454.1% | -$30M | — | $111M |
| 2023 | $802000 | -$73M | 0.0% | -10463.1% | -$56M | — | $142M |
| 2022 | $45M | $5M | 0.0% | -9.0% | -$21M | — | $194M |
| 2021 | $268000 | -$51M | 0.0% | -16873.5% | -$34M | — | $214M |
| 2020 | $5M | -$18M | 0.0% | -415.8% | -$11M | — | $43M |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | — | -$6M | — | — | -$3M | — | $66M |
| Dec '25 | $0 | -$11M | — | — | -$4M | — | $70M |
| Sep '25 | $0 | -$15M | — | — | -$11M | — | $74M |
| Jun '25 | — | -$21M | — | — | -$18M | — | $86M |
| Mar '25 | — | -$20M | — | — | -$15M | — | $99M |
| Dec '24 | $0 | -$21M | — | — | $13M | — | $111M |
| Sep '24 | $15M | -$8M | 0.0% | -62.7% | -$18M | — | — |
| Jun '24 | $0 | -$17M | — | — | -$12M | — | — |
| Mar '24 | $0 | -$15M | — | — | -$12M | — | — |
| Dec '23 | $0 | -$17M | — | — | -$19M | — | $142M |
| Sep '23 | $0 | -$14M | — | — | -$11M | — | $160M |
| Jun '23 | $334000 | -$24M | 0.0% | -7885.3% | -$20M | — | $173M |
| Mar '23 | $468000 | -$18M | 0.0% | -4590.6% | -$6M | — | $191M |
| Dec '22 | $6M | -$21M | 0.0% | -388.6% | -$12M | — | $194M |
| Sep '22 | $6M | $8M | 0.0% | 117.4% | $9M | — | $200M |
| Jun '22 | $17M | $16M | 0.0% | 77.6% | -$10M | — | $192M |
| Mar '22 | $15M | $3M | 0.0% | 4.4% | -$8M | — | $201M |
| Dec '21 | -$1000 | -$15M | 0.0% | 1666800.0% | -$8M | — | $214M |
| Sep '21 | $19000 | -$5M | 0.0% | -29136.8% | -$2M | — | $234M |
| Jun '21 | $35000 | -$16M | 0.0% | -48128.6% | -$15M | — | $244M |
Valuation over time
How the market has priced BRNS against its own fundamentals since 2023-11 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-earnings ratio has risen from 23.4× (Nov '23) to 28.0× (Dec '23).
- The price-to-sales ratio has fallen from 2.8× (Nov '23) to 2.0× (Nov '25).
P/E
P/S
Frequently asked questions
Is BRNS growing its revenue and profit?
See the revenue and net-income charts above for Barinthus Biotherapeutics plc.'s multi-year trend.
How much debt does BRNS have?
As of FY2025, Barinthus Biotherapeutics plc. reported — of total debt against $70M of cash; operating income covered interest expense -1383.4×.
What is BRNS's profit margin?
In FY2025, gross margin was —, operating margin —, and net margin —.
What is BRNS's P/E ratio?
As of Jun '26, Barinthus Biotherapeutics plc. traded at a price-to-earnings ratio of about 28.0× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.